Exosens (EXENS) AGM 2025 summary

Opening remarks and agenda

• Session opened by Jean-Hubert Vial, Chairman of the Board, with a detailed agenda covering group presentation, activity review, financial results, governance, remuneration, auditor reports, Q&A, and voting on resolutions.

Financial performance review

• 2024 revenue reached €394.1M, up 35% year-on-year, with adjusted EBITDA margin at 30.1%.

• Net profit grew 67% to €30.7M; free cash flow increased by €35M to €55.4M.

• Strong Q1 2025 performance with 21% revenue growth and 28% increase in gross margin.

• Capital structure strengthened post-IPO, reducing leverage ratio to 1.2x and increasing liquidity.

Board and executive committee updates

• Board comprised 8 members, 3 independents, 3 women, with 94.6% attendance.

• Proposal to appoint Dorianne Bonfils as new director, reinforcing Bpifrance's role.

• High participation rates in audit, nomination, and CSR committees, with majority independent members.